Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-31Actual
Enrollment · participants346Actual
Source updated2026-01-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.